Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ritter Pharmaceuticals has recruited first patient in the Phase 2 trial to evaluate RP-G28 in patients with symptoms associated with lactose intolerance.
Subscribe to our email newsletter
The Phase 2 randomized, double-blind, placebo-controlled trial will recruit around 80 patinets.
The study is designed to assess the efficacy, safety and tolerability of RP-G28 to treat the symptoms of lactose intolerance.
The company anticipates to release the initial results from the trial in 2012.
Ritter president and CEO Andrew Ritter said based on the results from their development work, they are excited to initiate this clinical study which is designed to more fully characterize the therapeutic potential of RP-G28 in treating lactose intolerance.